GSK plc (BVMF:G1SK34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 527.52B +17.2% |
| Revenue (ttm) | 225.81B +4.0% |
| Net Income | 40.15B +84.9% |
| EPS | 9.78 +86.6% |
| Shares Out | n/a |
| PE Ratio | 13.14 |
| Forward PE | 10.21 |
| Dividend | 1.66 (3.14%) |
| Ex-Dividend Date | May 14, 2026 |
| Volume | 38 |
| Open | 52.50 |
| Previous Close | n/a |
| Day's Range | 52.50 - 52.75 |
| 52-Week Range | 39.98 - 63.24 |
| Beta | 0.29 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion deal
After shedding its oncology business just over a decade ago, GSK is building it back with a $10.6 billion deal.
Tuesday's Morning Movers: MU Rebounds, ON PT Increases & GSK Buys NUVL
Diane King Hall discusses this morning's top moving stocks by highlighting Micron (MU) as it rallies back after Friday's sell-off. She also touches on Wells Fargo raising its ON Semiconductor's (ON) p...
Nuvalent downgraded to Hold from Buy at Stifel
Stifel downgraded Nuvalent (NUVL) to Hold from Buy with a price target of $124, down from $135, after GSK (GSK) announced that it has entered into an agreement to acquire…
5 Things to Know Before the Stock Market Opens
Stock futures are pointing to a higher open Tuesday as the market looks to extend its recovery from last week's losses; President Trump said last night that the U.S. and Iran are close to a "very, ver...
GSK agrees to acquire Nuvalent for $124 per share
GSK plc (GSK) announced that it has entered an agreement to acquire Nuvalent (NUVL) a Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies, f...
GSK's $10.6B Nuvalent takeover fails to impress investors as shares fall: here's why
GlaxoSmithKline is making its largest oncology acquisition in years with a $10.6 billion deal for US-based cancer drug developer Nuvalent, betting that a trio of promising lung cancer therapies can he...
Nuvalent agrees to acquire Nuvalent for $124 per share
GSK plc (GSK) announced that it has entered an agreement to acquire Nuvalent (NUVL) a Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies, f...
Cancer-Drug Stock Jumps 39% on $10.6 Billion GSK Deal. Why It's a Surprise Move.
GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where the stock traded as of Monday's close.
London's FTSE 100 falls as GSK slides after Nuvalent deal
The UK's benchmark FTSE 100 index moved lower on Tuesday, pressured by losses in healthcare giant GSK after the company announced plans to acquire shares of US-based drug developer Nuvalent in a deal ...
GSK plc Transcript: M&A announcement
The acquisition brings two late-stage, best-in-class oncology assets targeting ALK and ROS1 mutations, accelerating entry into lung cancer and supporting long-term revenue growth. Financial discipline, rapid integration, and strong physician feedback underpin confidence in clinical and commercial success.
GSK plc Slides: M&A announcement
GSK plc has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
GSK plc Press release: M&A announcement
GSK plc issued a press release on June 9, 2026, disclosing material business information to investors.
GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down
U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it ...
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are currently under review by the FDA for approval this year.
UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion.
Why GSK May Acquire Nuvalent — Report Points to $9B+ Deal Talks
GlaxoSmithKline ($GSK) is reportedly in talks to acquire cancer drugmaker Nuvalent ($NUVL). According to The Financial Times, citing people familiar with the matter, the two companies are in active di...
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
UK pharmaceutical group GSK is in talks to acquire oncology biotech Nuvalent for more than $9 billion, according to a Financial Times report. The companies have been in discussions with the aim of fin...
GSK in talks to buy Nuvalent for $9B-$10B, FT says
GSK (GSK) is in talks to buy Nuvalent (NUVL) in a potential deal that could value the cancer drugmaker at between $9B and $10B, people familiar with the matter told…
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion, FT reports
UK pharmaceutical group GSK is in talks to buy cancer drugmaker Nuvalent for more than $9 billion, the Financial Times reported on Monday, citing people familiar with the matter.
Engitix Announces Strategic Collaboration with GSK to Advance First-in-Class Targets for Liver Fibrosis Regression
Collaboration leverages Engitix's human ECM Platform to identify high-confidence targets for liver fibrosis regression Collaboration leverages Engitix's human ECM Platform to identify high-confidence ...
GSK PLC (GSK) Shares Surge 3.1% -- What GF Score of 77 Tells Investors
GSK PLC (GSK) Shares Surge 3.1% -- What GF Score of 77 Tells Investors
FTSE 100 drops amid China banking concerns and falling oil prices
The UK's benchmark FTSE 100 index fell to its lowest level in more than two weeks on Thursday, weighed down by sharp declines in Asia-focused lenders and miners after reports of tighter offshore banki...
GSK Crosses Above Key Moving Average Level
In trading on Wednesday, shares of GSK plc (Symbol: GSK) crossed above their 200 day moving average of $49.37, changing hands as high as $49.87 per share. GSK plc shares are currently trading up about...
GSK plc Transcript: Jefferies Global Healthcare Conference 2026
The discussion highlighted a strategic pivot to precision oncology, leveraging both internal innovation and external acquisitions. Key assets like B7-H4, B7-H3, dostarlimab, and velzatinib are advancing, with significant data readouts expected in the next year to support long-term growth.
GSK Launches PrEP Wisdom Campaign for HIV Prevention Awareness
GSK Launches PrEP Wisdom Campaign for HIV Prevention Awareness